Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial

BACKGROUND: This exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial examined whether the previously reported benefit of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) mass (LVM) regression differs between individuals of South Asian and non-Sout...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbour, William, Wolff, Erika, Puar, Pankaj, Hibino, Makoto, Bakbak, Ehab, Krishnaraj, Aishwarya, Verma, Raj, Verma, Meena, Quan, Adrian, Yan, Andrew T., Connelly, Kim A., Teoh, Hwee, Mazer, C. David, Verma, Subodh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648366/
https://www.ncbi.nlm.nih.gov/pubmed/37964221
http://dx.doi.org/10.1186/s12872-023-03549-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648366/
https://www.ncbi.nlm.nih.gov/pubmed/37964221
http://dx.doi.org/10.1186/s12872-023-03549-5

Ejemplares similares